Progress and Challenges in the Study of Bacteriophage Therapy for Carbapenem-Resistant Klebsiella Pneumoniae Infection
10.12259/j.issn.2095-610X.S20250621
- VernacularTitle:噬菌体治疗碳青霉烯类耐药肺炎克雷伯菌感染研究进展与挑战
- Author:
Yahong SUN
1
;
Xiaoyu YANG
;
Rui ZHENG
Author Information
1. 昆明理工大学医学院,云南 昆明 650500
- Keywords:
Carbapenem-resistant Klebsiella pneumoniae;
Antibiotic;
Bacteriophage;
Bacteriophage therapy
- From:
Journal of Kunming Medical University
2025;46(6):163-170
- CountryChina
- Language:Chinese
-
Abstract:
Carbapenem-resistant Klebsiella pneumoniae(CRKP),as a superbug pathogen,has become a critical global public health threat,with significantly increased detection rates especially in ICU and immunocompromised patients.Traditional antibiotics are progressively losing efficacy,and CRKP's antibiotic resistance spectrum continues to expand,presenting enormous clinical treatment challenges.Bacteriophages,as viruses specifically infecting bacteria,have emerged as a new therapeutic strategy for alternative or complementary antibiotic treatment due to their strong lytic capabilities,excellent biofilm penetration,low side effects,and ability to synergize with antibiotics.This article systematically reviews the epidemiology and resistance mechanisms of CRKP,principles and mechanisms of bacteriophage therapy,research progress(including in vitro experiments,animal models,and clinical applications),combined therapies,and their advantages and challenges.By incorporating the latest research,the article also proposes future development directions,including constructing genetically engineered bacteriophages,designing"intelligent bacteriophages"through synthetic biology,and establishing clinical regulatory systems.Bacteriophage therapy offers a potential breakthrough in combating CRKP,but its standardization,broad-spectrum applicability,and clinical translation pathways still require in-depth exploration and standardization.
